Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 17/20 | 1.00 |
| ▸ | KDM5C | P41229 | 11/20 | 1.00 |
| ▸ | KDM5A | P29375 | 9/20 | 1.00 |
| ▸ | KDM4A | O75164 | 4/20 | 1.00 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 1.00 |
| ▸ | KDM6B | O15054 | 1/20 | 1.00 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.81 |
| ▸ | KDM5D | Q9BY66 | 1/20 | 0.81 |
| ▸ | KDM4B | O94953 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25380189 | 0.90 | KDM5B (1.00) | KDM5BKDM5CKDM5AKDM4AKDM2B | |
| SCHEMBL15637682 | 0.89 | KDM5B (0.86) | KDM5BKDM5CKDM5AKDM4AKDM2B | |
| SCHEMBL18708312 | 0.89 | KDM5B (0.80) | KDM5BKDM5CKDM5AKDM4AKDM2B | |
| SCHEMBL29373338 | 0.88 | KDM5B (1.00) | KDM5BKDM5CKDM5AKDM4AKDM2B | |
| SCHEMBL15637431 | 0.88 | KDM5B (1.00) | KDM5BKDM5CKDM5AKDM4AKDM2B | |
| SCHEMBL15637033 | 0.87 | KDM5B (0.77) | KDM5BKDM5CKDM5AKDM4AKDM2B | |
| SCHEMBL18286849 | 0.87 | KDM5B (0.82) | KDM5BKDM5CKDM5AKDM4AKDM2B | |
| SCHEMBL17364565 | 0.86 | KDM5B (0.75) | KDM5BKDM5CKDM5AKDM4AKDM2B | |
| SCHEMBL19676470 | 0.85 | KDM5B (0.86) | KDM5BKDM5CKDM5AKDM4AKDM2B | |
| SCHEMBL15636176 | 0.85 | KDM5B (0.79) | KDM5BKDM5CKDM5AKDM4AKDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120137885-A | Culture solution additive for improving embryo development potential and application thereof | 山东大学 | 2025-06-13 | — | — | CN | claimed |
| WO-2024233765-A1 | THERAPEUTIC APPROACH TO BLOCK TERMINAL EXHAUSTION OF T CELLS AND SYNERGIZE THE EFFICACY OF T CELL IMMUNOTHERAPIES | OHIO STATE INNOVATION FOUNDATION (US) | 2024-11-14 | — | — | WO | claimed |
| EP-4058604-B1 | COMPOSITIONS AND METHODS FOR REGULATING EGFR AMPLIFICATION IN CANCER CELLS FOR IMPROVING EGFR-TARGETED ANTI-CANCER AGENT | INSTITUTE FOR CANCER RES (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250276997-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2025-09-04 | — | — | US | disclosed |
| CN-120137885-A | Culture solution additive for improving embryo development potential and application thereof | 山东大学 | 2025-06-13 | — | — | CN | disclosed |
| WO-2025053163-A1 | COMPOUND OR SALT THEREOF, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITION CONTAINING COMPOUND OR SALT THEREOF, AND METHOD FOR PRODUCING SAME | セレイドセラピューティクス株式会社 | 2025-03-13 | — | — | WO | disclosed |
| WO-2024233765-A1 | THERAPEUTIC APPROACH TO BLOCK TERMINAL EXHAUSTION OF T CELLS AND SYNERGIZE THE EFFICACY OF T CELL IMMUNOTHERAPIES | OHIO STATE INNOVATION FOUNDATION (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240269290-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2024-08-15 | — | — | US | disclosed |
| US-20240139197-A1 | INHIBITION OF KDM5A FOR PROMOTING ANTIGEN PRESENTATION, INCREASING CD8+ T CELL INFILTRATION AND BOOSTING ANTI-TUMOR IMMUNE RESPONSE | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2024-05-02 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| EP-3023415-A1 | INHIBITORS OF HISTONE DEMETHYLASES | Epitherapeutics ApS (DK) | 2016-05-25 | — | — | EP | disclosed |
| EP-2903968-A1 | INHIBITORS OF HISTONE DEMETHYLASES | Epitherapeutics ApS (DK) | 2015-08-12 | — | — | EP | disclosed |
| US-20150203453-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20150203453-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20150203453-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20140371195-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371195-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371195-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
| WO-2014053491-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (DK) | 2014-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203453-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EHMT1, KDM1B, EHMT2 | KDM5B 34/4885KDM5C 31/4885KDM5A 25/4885 |
| US-20140371195-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EHMT1, KDM1B, EHMT2 | KDM5B 34/4885KDM5C 31/4885KDM5A 24/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | KDM5B 3369/4885KDM5C 3176/4885KDM5A 3261/4885 |
| US-20240139197-A1 | INHIBITION OF KDM5A FOR PROMOTING ANTIGEN PRESENTATION, INCREASING CD8+ T CELL INFILTRATION AND BOOSTING ANTI-TUMOR IMMUNE RESPONSE | KDM5A, KDM5B, KDM5C | KDM5B 2/4885KDM5C 3/4885KDM5A 1/4885 |
| US-20250276997-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2, ATXN2L, ATXN10 | KDM5B 2073/4885KDM5C 2591/4885KDM5A 3270/4885 |
| US-20240269290-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | KDM5B 3160/4885KDM5C 3145/4885KDM5A 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.